Genentech makes its first-ever acquisition

Article Abstract:

San Francisco, California-based Genentech is planning to pay $919 million for Houston, Texas-based Tanox in order to get the rights to Xolair (omalizumab), an anti-IgE antibody to treat asthma and severe allergies. Genentech has signed a license agreement with the Swiss firm AC Immune Ltd. to develop antibeta-amyloid antibodies for treating Alzheimer disease, whereas Tanox has developed its own IgE antibody, TNX-9021, for treating peanut allergy.

Drugs, Alliances, partnerships, Licensing/Sales Agreements, United States, Biological products industry, Licensing agreements, Company licensing agreement, Genentech Inc., Tanox Inc., DNA, Xolair (Medication)

---

China approves first gene therapy

Article Abstract:

China accorded approval for the commercial production of gene therapy that will hit the market in early January 2004. Gendicine, the world's first commercial gene therapy from Shenzhen SiBiono GenTech, Shenzhen, China, uses an adenoviral vector, which could cost the company more than RMB 80 ($9.6) million to develop in addition to research grants they received from the government.

China, Government domestic functions, Gene therapy, Health policy

---

Enfuvirtide

Article Abstract:

Enfuvirtide was approved for treatment of HIV-1 infection in combination with other antiretroviral agents in treatment. Enfuviritde is an anti-HIV drugs that inhibit virus entry into host cells.

Usage, Drug therapy, HIV (Viruses), HIV, Antiviral agents, Anti-HIV agents, Enfuvirtide (Medication)

Similar abstracts:

• Abstracts: HR systems drive successful postacquisition integration at General Mills. Making a profit . . . and a difference: HP invents an organization to drive sustainability
• Abstracts: Currents: articles in brief. Rep 'brings it on home' for the president. Furniture First wakes up to bedding
• Abstracts: JPM steals the show. Ads that come to life. EPB ACQUISITIONS

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.